Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions

American Journal of Clinical Pathology

Volumn 126, Issue 1, 2006, Pages 59-66

  Saggiorato, Enrico ^a   Bergero, Nicoletta ^a   Volante, Marco ^a   Bacillo, Elisa ^a   Rosas, Rosj ^a   Gasparri, Guido ^a   Orlandi, Fabio ^a   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Galectin 3; Hyperparathyroidism; Immunohistochemistry; Ki 67; Parathyroid gland; Parathyroid hyperplasia; Parathyroid neoplasm

Indexed keywords

GALECTIN 3; KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID DISEASE; PARATHYROID HYPERPLASIA; PARATHYROID TUMOR; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33745787906     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/9NXP7FRF87MU2PCK     Document Type: Article

References (37)

1. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17(suppl 2):N18-N23.
2. Apel RL, Asa SL. The parathyroid glands. In: LiVolsi VA, Asa SL, eds. Endocrine Pathology. Philadelphia, PA: Churchill Livingstone; 2002:103-147.
3. Mariani G, Gulec SA, Rubello D, et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med. 2003;44:1443-1458.
4. Rosai J. Parathyroid glands. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology. 9th ed. New York, NY: Mosby; 2004:515-614.
5. Dwight T, Nelson AE, Marsh DJ, et al. Parathyroid tumorigenesis in association with primary hyperparathyroidism. Curr Opin Endocrinol Diabetes. 2002;9:51-60.
6. Abboud B, Sleilaty G, Helou E, et al. Existence and anatomic distribution of double parathyroid adenoma. Laryngoscope. 2005;115:1128-1131.
7. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and Genetics of Tumours of the Endocrine Organs. Lyon, France: IARC Press; 2004:124-132. World Health Organization Classification of Tumours.
8. Morrison C, Farrar W, Kneile J, et al. Molecular classification of parathyroid neoplasia by gene expression profiling. Am J Pathol. 2004;165:565-576.
9. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64:7405-7411.
10. Abbona GC, Papotti M, Gasparri G, et al. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 1995;26:135-138.
11. Erickson LA, Jin L, Wollan P, et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol. 1999;23:288-295.
12. Bergero N, De Pompa R, Sacerdote C, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol. 2005;36:908-914.
13. Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol. 2003;34:54-64.
14. Haven CJ, van Puijenbroek M, Karperien M, et al. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol. 2004;202:86-94.
15. Kammori M, Nakamura K, Ogawa T, et al. Demonstration of human telomerase reverse transcriptase (hTERT) in human parathyroid tumours by in situ hybridization with a new oligonucleotide probe. Clin Endocrinol (Oxf). 2003;58:43-48.
16. Onoda N, Ogisawa K, Ishikawa T, et al. Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today. 2004;34:389-393.
17. Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf). 2004;60:99-106.
18. Tuccari G, Abbona GC, Guiffre G, et al. AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands. Virchows Arch. 2000;437:298-303.
19. Lumachi F, Ermani M, Marino F, et al. Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma. Endocr Relat Cancer. 2004;11:563-569.
20. Falchetti A, Bale AE, Amorosi A, et al. Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab. 1993;76:139-144.
21. Erickson LA, Jalal SM, Harwood A, et al. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2004;28:578-584.
22. Abbona G, Papotti M, Gasparri G, et al. Recurrence in parathyroid hyperplasias owing to secondary hyperparathyroidism is predicted by morphological patterns and proliferative activity values. Endocr Pathol. 1996;7:55-61.
23. Erickson LA, Jin L, Wollan PC, et al. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol. 1998;11:169-174.
24. DeLellis RA. Tumors of the Parathyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1993:53-63. Atlas of Tumor Pathology; Third series, Fascicle 6.
25. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid "follicular neoplasms" in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005;12:305-317.
26. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020.
27. Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5152-5158.
28. Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest. 2004;27:311-317.
29. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-1650.
30. Ross N, Leung CS, Kovacs K, et al. Parathyroid nodules in a patient with chronic renal failure: hyperplasia or neoplasia? Endocr Pathol. 1993;4:100-104.
31. Liu L, Sakai T, Sano N, et al. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J. 2004;380:31-41.
32. Dumic J, Laue G, Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem. 2000;10:149-158.
33. Fogel S, Guittaut M, Legrand A, et al. The tat protein of HIV-1 induces galectin-3 expression. Glycobiology. 1999;9:383-387.
34. Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305-328.
35. Hsu DK, Yang RY, Pan Z, et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol. 2000;156:1073-1083.
36. Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J. 2004;19:575-581.
37. Seki N, Hashimoto N, Sano H, et al. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism. 2003:52:1558-1563.